PepGen withdraws PGN-EDODM1 Phase 1 timeline guidance pending FDA clinical hold

PepGen Inc.

Withdrawing prior guidance to initiate a Phase 1 study of PGN-EDODM1 in DM1 in H1 2023.
Awaiting official clinical hold letter from FDA; pausing additional regulatory filings to address the hold.
CEO committed to working with FDA to lift the hold and start study as quickly as feasible.
Company remains focused on advancing Phase 2 CONNECT1-EDO51 study in Duchenne muscular dystrophy, cleared by Health Canada in May 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.